Naslov: | Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer : final analysis of the GioTag study |
---|
Avtorji: | ID Hochmair, Maximilian J (Avtor) ID Morabito, Alessandro (Avtor) ID Hao, Desiree (Avtor) ID Yang, Cheng-Ta (Avtor) ID Soo, Ross A (Avtor) ID Yang, James C-H (Avtor) ID Gucalp, Rasim (Avtor) ID Halmos, Balazs (Avtor) ID Märten, Angela (Avtor) ID Čufer, Tanja, Klinika Golnik, Medicinska fakulteta UL (Avtor) |
Datoteke: | PDF - Predstavitvena datoteka, prenos (1,58 MB) MD5: E5B817D1334C093553F6EC429C0A7178
PDF - Priloga, prenos (1,10 MB) MD5: C384BC86E3FD51111A4BAD50BC370759
URL - Izvorni URL, za dostop obiščite https://www.futuremedicine.com/doi/pdf/10.2217/fon-2020-0740
|
---|
Jezik: | Angleški jezik |
---|
Tipologija: | 1.01 - Izvirni znanstveni članek |
---|
Organizacija: | UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
|
---|
Povzetek: | Aim: Final overall survival (OS) and time on treatment analysis of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib and osimertinib. Patients & methods: Patients (n = 203) had T790M-positive disease following first-line afatinib and started osimertinib treatment >/=10 months before data entry. Primary outcome was time on treatment; OS analysis was exploratory. Results: Median time on treatment with afatinib and osimertinib was 27.7 months (90% CI: 26.7-29.9). Median OS was 37.6 months (90% CI: 35.5-41.3); median OS was 41.6 and 44.8 months in Del19-positive patients and Asian patients, respectively. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib was associated with encouraging outcomes in patients with EGFR mutation-positive NSCLC, especially in Del19-positive patients and Asian patients. |
---|
Ključne besede: | non-small cell lung carcinoma -- therapy, drug therapy, afatinib, osimertinib, GioTag study |
---|
Status publikacije: | V tisku |
---|
Verzija publikacije: | Objavljena publikacija |
---|
Kraj izida: | Velika Britanija |
---|
Založnik: | Future Medicine Ltd |
---|
Leto izida: | 2020 |
---|
Št. strani: | str. [1-10] |
---|
Številčenje: | Vol. 16, no. |
---|
PID: | 20.500.12556/DiRROS-12685 ![Povezava se odpre v novem oknu Novo okno](teme/dirros/img/NovoOkno.png) |
---|
UDK: | 616-006 |
---|
ISSN pri članku: | 1744-8301 |
---|
DOI: | 10.2217/fon-2020-0740 ![Povezava se odpre v novem oknu Novo okno](teme/dirros/img/NovoOkno.png) |
---|
COBISS.SI-ID: | 37424899 ![Povezava se odpre v novem oknu Novo okno](teme/dirros/img/NovoOkno.png) |
---|
Avtorske pravice: | © 2020 Maximilian J. Hochmair and other authors |
---|
Opomba: | Nasl. z nasl. zaslona;
Opis vira z dne 14. 11. 2020;
Soavtorica iz Slovenije: Tanja Cufer;
|
---|
Datum objave v DiRROS: | 18.11.2020 |
---|
Število ogledov: | 1667 |
---|
Število prenosov: | 1356 |
---|
Metapodatki: | ![Izvoz v DC-RDF DC-RDF](teme/dirros/img/icon_dc_rdf.gif) |
---|
:
|
Kopiraj citat |
---|
| | | Objavi na: | ![Bookmark and Share](teme/dirros/img/addtoany.png) |
---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |